Loading stock data…
$17.47-0.22 (-1.24%)
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Beta Bionics, Inc. in the Healthcare sector is trading at $17.47 with a market capitalization of $942M. Wall Street consensus targets $24.24 (14 analysts), implying a +38.8% move over the next 12 months. The stock is currently 47% below its 52-week high of $32.71, remaining 14.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $32.01M↑ | $27.63M↓ | $32.12M↑ | $27.25M↑ | $23.24M |
| Gross Profit | $18.90M↑ | $16.44M↓ | $18.94M↑ | $15.12M↑ | $12.50M |
| Operating Income | -$25.58M↓ | -$24.27M↓ | -$16.12M↑ | -$17.04M↑ | -$19.87M |
| Net Income | -$23.40M↓ | -$21.89M↓ | -$13.47M↑ | -$14.21M↑ | -$16.87M |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas,...